Peptide library
CT-388
Your guide to this compound.
Evidence in perspective
Small sequential phase I cohorts and pooled placebo data are appropriate for early development but limited for comparative efficacy. No formal efficacy hypothesis testing was performed; preclinical signaling bias does not establish superiority in people.
About this assessment
Selected full-text methods/results or correction sections assessed.
This assessment covers selected sources and sections. It is not a systematic review, formal risk-of-bias score, or clinician sign-off.
Editorial assessment · 2026-09-07
Who was studied
Preclinical models and participants with overweight or obesity in phase 1.
What the sources found
The primary report studied weight and glucose outcomes during early development.
What remains unknown
Early trial findings do not establish long-term outcomes or equivalence to other incretin drugs.
How it works
Activates GLP-1 and GIP receptors with signaling biased toward cAMP.
Activates GLP-1 and GIP receptors with signaling biased toward cAMP. Early trial findings do not establish long-term outcomes or equivalence to other incretin drugs.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Safety details remain incomplete in this snapshot; absence of a listed effect does not mean it was excluded.
Contraindications
- This snapshot is not a complete contraindication or interaction review.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
References
Primary publication · PMID 41319798
PMID: 41319798
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.